NUPLAZID is an FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis.
Support for managing
Parkinson’s
disease–related hallucinations
and delusions
NUPLAZID is an FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis.
Support for managing
Parkinson’s
disease–related hallucinations
and delusions
These organizations can provide you with more information about the nonmotor symptoms associated with PD.
The Parkinson’s Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience, and passion of our global Parkinson’s community.
The American Parkinson Disease Association (APDA) is the largest grassroots network dedicated to fighting PD and works tirelessly to assist those with PD live life to the fullest in the face of this chronic, neurological disorder. APDA provides support nationally through its network of Chapters and Information & Referral (I&R) Centers, as well as a national Research Program and Centers for Advanced Research.
The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson’s and to ensuring the development of improved therapies for those living with the disease today through an aggressively funded research agenda.
The Davis Phinney Foundation provides resources and connections that enable people living with Parkinson's to take action that can immediately improve their quality of life. The organization impacts hundreds of thousands of individuals and families each year through community programs, the funding of quality of life research, and extensive online content.
Parkinson & Movement Disorder Alliance (PMD Alliance) is a community of movers and motivators working hand-in-hand with those living with a diagnosis, their care partners, adult children, and support group leaders to deliver education and connection to those impacted by movement disorders.
See how NUPLAZID can help with
PD-related hallucinations and delusions
IMPORTANT SAFETY INFORMATION and INDICATION
WARNING: INCREASED RISK OF DEATH IN ELDERLY PATIENTS WITH DEMENTIA–RELATED PSYCHOSIS
Medicines like NUPLAZID can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia).
NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
NUPLAZID may cause serious side effects including:
QT Interval Prolongation: NUPLAZID may increase the risk of changes to your heart rhythm. This risk may increase if NUPLAZID is taken with certain other medications known to prolong the QT interval. Tell your healthcare provider about all the medicines you take or have recently taken.
Do not take NUPLAZID if you have certain heart conditions that change your heart rhythm. It is important to talk to your healthcare provider about this possible side effect. Call your healthcare provider if you feel a change in your heartbeat.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
You can also call Acadia Pharmaceuticals Inc. at 1‑844‑4ACADIA (1‑844‑422‑2342).
NUPLAZID is a prescription medicine used to treat hallucinations and delusions associated with Parkinson’s disease psychosis.
The recommended dose of NUPLAZID is one 34 mg capsule once per day, taken by mouth.
NUPLAZID is available as 34 mg capsules and 10 mg tablets.
Please read the full Prescribing Information, including Boxed WARNING.
